Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects: KSS Parveen et al.
1. 请及时下载文件确认是否正确, 系统将在 2026-08-07 10:08:42 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
KS Soya Parveen, K Sreekanth, N Radhakrishnan…
Drugs, 2026
Springer
Polidocanol is a widely recognised drug for its effectiveness as a sclerosant in the treatment of lymphovenous disease. The versatility and minimal invasiveness of polidocanol make it a favoured treatment modality for chronic venous disease (CVD) and other venous and vascular disorders. Especially, polidocanol foam sclerotherapy achieves high closure rates and efficiency compared to thermal ablation, in cases of venous hypertension affecting small tributary veins of the peripheral venous system. The underlying pathophysiology of these …
